| Patents for A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291) |
|---|
| 02/23/2010 | US7666390 DTPA derivatives and metal complexes thereof, and radiation source and contrast agent including the metal complexes |
| 02/23/2010 | US7666389 Method of imaging cell death in vivo |
| 02/23/2010 | CA2198899C Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| 02/18/2010 | WO2009112488A4 Polyether polyol dendron conjugates with effector molecules for biological targeting |
| 02/18/2010 | WO2009046281A3 Injectable particles |
| 02/18/2010 | US20100041827 Multilayer binding; lamellar surface structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure; organized mobile multifunctional conjugate (OMMC) assembly |
| 02/18/2010 | US20100041826 Multilayer binding; lamellar surface structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure; organized mobile multifunctional conjugate (OMMC) assembly |
| 02/18/2010 | US20100041082 Methods for determining the metabolism of sugars and fats in an individual |
| 02/18/2010 | US20100040545 Radiolabelling methods |
| 02/18/2010 | US20100040544 Method for managing patients with cancer |
| 02/18/2010 | US20100040543 99mTc-LABELED 19 AMINO ACID CONTAINING PEPTIDE FOR USE AS PHOSPHATIDYLETHANOLAMINE BINDING MOLECULAR PROBE AND RADIOPHARMACEUTICAL |
| 02/18/2010 | US20100040542 Chelator conjugates |
| 02/18/2010 | US20100040541 Structural Variants of Antibodies for Improved Therapeutic Characteristics |
| 02/18/2010 | US20100040540 Anti cd44 antibodies for eradicating leukaemic stem cells and breast cancer stem cells |
| 02/18/2010 | US20100040539 Vector System |
| 02/18/2010 | US20100040538 Polymer Systems for Lung Volume Reduction Therapy |
| 02/18/2010 | US20100040537 antibodies that are wild-type, chimeric, CDR grafted and humanized; disease or disorder in which prostaglandin E2 activity is detrimental, such as cancer, atuoimmune diseases, inflammatory diseases |
| 02/18/2010 | DE102008039417A1 Mittel zum Nachweis und zur Behandlung von Prostatazellen Means for the detection and treatment of prostate cells |
| 02/18/2010 | CA2734335A1 Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof |
| 02/17/2010 | EP2153829A1 Methods of preventing, treating and diagnosing disorders of protein aggregation |
| 02/17/2010 | CN101648028A vitamin-targeted imaging agents |
| 02/17/2010 | CN101648027A Positron emission tomography (PET) diagnostic radioactive drug and preparation method thereof |
| 02/16/2010 | US7662922 Canola protein isolate compositions |
| 02/16/2010 | US7662857 Diagnostic agents for pancreatic exocrine function |
| 02/16/2010 | US7662788 Abuse-resistant amphetamine prodrugs |
| 02/16/2010 | US7662787 lisdexamfetamine, lisdexamfetamine dimesylate and lisdexamfetamine hydrochloride; attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity |
| 02/16/2010 | US7662775 Method for screening agents for the treatment of diabetes |
| 02/16/2010 | US7662768 Transdifferentiation of pancreatic acinar cells |
| 02/16/2010 | US7662767 inhibiting complexation of intercalating molecules with polynucleotides; using modified xanthine molecules as a binding agent; drug delivery system for compounds that have low solubility in aqueous media, including anti-neoplastic agents |
| 02/16/2010 | US7662383 Epitope bound by MAbs A, B, C or D, where MAbs A, B, C and D have given variable domains; chimeric or humanized for side effect reduction; polymerase chain reaction |
| 02/16/2010 | US7662378 administering anti-CEA (carcinogenicembryonic antigen) monoclonal antibody (MAb) or fragment and a drug selected from vincristine, doxorubicin, dacarbazine (DTIC), cyclophosphamide, CPT-11, oxaliplatin, gemcitabine and 5-fluorouracil/leucovorin |
| 02/16/2010 | US7662374 Dual-specificity antibody having specificity for both an activated erbB2 receptor and erbB1 dimers, without significant affinity for monomeric EGFr that is not activate; specificity of the antibodies is due to their recognition and binding of activation epitopes; diagnosis, imaging and for treating tumor |
| 02/16/2010 | US7662360 boron neutron capture therapy |
| 02/16/2010 | CA2415295C Radioligand and binding assay |
| 02/16/2010 | CA2309154C Substituted porphyrins |
| 02/11/2010 | WO2010017500A2 Anti-pancreatic cancer antibodies |
| 02/11/2010 | US20100034826 Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and methods for using anti-ptk7 antibodies |
| 02/11/2010 | US20100034741 Imaging agents and methods of imaging alpha7-nicotinic cholinergic receptor |
| 02/11/2010 | US20100034740 Radiofluorination methods |
| 02/11/2010 | US20100034739 Fungus-Specific Imaging Agents |
| 02/11/2010 | US20100034738 Structural Variants of Antibodies for Improved Therapeutic Characteristics |
| 02/11/2010 | US20100034737 Junctional adhesion molecule-c (jam-c) binding compounds and methods of their use |
| 02/11/2010 | US20100034736 Identification of cancer stem cells using genetic markers |
| 02/11/2010 | US20100034735 Targeted nanoparticles for cancer diagnosis and treatment |
| 02/11/2010 | US20100034734 System and method for quantitative molecular breast imaging |
| 02/11/2010 | CA2731438A1 Anti-pancreatic cancer antibodies |
| 02/10/2010 | EP2151250A1 Vitamin-Targeted imaging agents |
| 02/09/2010 | US7659400 Radiolabelled benzamide analogues, their synthesis and use in diagnostic imaging |
| 02/09/2010 | US7659373 Producing such EPO products characterized by a high proportion of N-acetyl-lactosamine units or/and tetraantennary branches in the carbohydrate structure |
| 02/09/2010 | US7659364 Decyclization of an oxazolidinone compound; N-methylmethionine chemical intermediates |
| 02/09/2010 | US7659254 Abuse-resistant amphetamine prodrugs |
| 02/09/2010 | US7659253 Abuse-resistant amphetamine prodrugs |
| 02/09/2010 | US7658923 Anti-CD26 monoclonal antibodies as therapy for diseases associated with cells expressing CD26 |
| 02/09/2010 | US7658917 A beta aggregation core domain and a modifying group coupled thereto such that the compound alters the aggregation or inhibits the neurotoxicity of natural beta amyloid peptides when contacted with the peptides. |
| 02/09/2010 | US7658910 Preparation of radiolabelled haloaromatics via polymer-bound intermediates |
| 02/09/2010 | CA2485977C Short chain polymer for enhancing the bioadhesiveness of polymers on mucosal membrane |
| 02/09/2010 | CA2353612C Boron neutron capture therapy using pre-targeting methods |
| 02/06/2010 | CA2660507A1 Targeted nanoparticles for cancer diagnosis and treatment |
| 02/04/2010 | WO2010013139A2 Radionuclide-labeled erlotinib |
| 02/04/2010 | WO2010013136A2 Active particles for bio-analytical applications and methods for their preparation |
| 02/04/2010 | WO2009150139A3 Indolyl-pyridazinyl-diazabicyclononane derivatives in labelled and unlabelled form and their use in diagnostic methods |
| 02/04/2010 | US20100028936 Detection of cancer cells in vitro using sigma-2 receptor ligands as radiotracers |
| 02/04/2010 | US20100028258 Radioactive Diagnostic Imaging Agent |
| 02/04/2010 | US20100028257 Pharmaceutical compounds |
| 02/04/2010 | US20100028256 Differential gene expression in physiological and pathological angiogenesis |
| 02/03/2010 | EP2149567A1 Cyclic polyamines for binding phosphatidylserine |
| 02/03/2010 | CN100586485C Methods of radiofluorination of biologically active vectors |
| 02/03/2010 | CN100586484C Thorium-227 for use in radiotherapy of soft tissue disease |
| 02/03/2010 | CN100586483C Medicine in use for diagnosing gastric cancer, and preparation method |
| 02/02/2010 | US7655630 Abuse-resistant amphetamine prodrugs |
| 02/02/2010 | US7655629 Peptides and their use for the treatment of HIV infections |
| 02/02/2010 | US7655621 Cross-linked glycopeptide-cephalosporin antibiotics |
| 02/02/2010 | US7655618 Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
| 02/02/2010 | CA2507923C Tetracyclic 3-substituted indoles having serotonin receptor affinity |
| 02/02/2010 | CA2407520C Sigma-2 receptors as biomarkers of tumor cell proliferation |
| 01/28/2010 | WO2010011964A2 Imaging agents useful for identifying ad pathology |
| 01/28/2010 | WO2010010913A1 Method for producing bsh derivative and bsh derivative |
| 01/28/2010 | WO2010010912A1 OPTICALLY ACTIVE α-AMINO ACID INTO WHICH BSH IS INTRODUCED AND METHOD FOR SYNTHESIZING THE SAME |
| 01/28/2010 | WO2010010079A1 Diagnostic agents selective against metalloproteases |
| 01/28/2010 | WO2008083054A3 Radioactive ligands for cardiac beta1 adrenoreceptor for imaging congestive heart failure |
| 01/28/2010 | US20100022498 Steroids as agonists for fxr |
| 01/28/2010 | US20100021381 Natriuretic peptide-mediated imaging of atherosclerotic plaque |
| 01/28/2010 | US20100021380 Dieghylenetriaminepentaacetic acid (dtpa)-modified ferrofluid, preparation method of the same and uses of the same in preparation of peptide ferrofluid |
| 01/28/2010 | US20100021379 Chemical Antibodies for Immunotherapy and Imaging |
| 01/28/2010 | US20100021378 Imaging protocols |
| 01/28/2010 | CA2731738A1 Imaging agents useful for identifying ad pathology |
| 01/27/2010 | EP2147684A1 Diagnostic Agents Selective Against Metalloproteases |
| 01/27/2010 | EP2146995A1 Folate-conjugates and corresponding metal-chelate complexes for use in diagnostic imaging and radiotherapy |
| 01/27/2010 | EP2146944A1 18f-labelled folates |
| 01/27/2010 | EP2146753A2 18f fluoro-benzoyl labelled biological active compounds as diagnostic imaging agents as well as benzotriazol-1-yloxy-benzoyl , 2,5-dioxo-pyrrolidin-1-yloxy)benzoyl and trimethylammonio-benzoyl precursers thereof |
| 01/27/2010 | EP2146632A1 Compositions and methods for cellular imaging and therapy |
| 01/27/2010 | CN101636183A Method for production of radiation diagnostic imaging agent |
| 01/26/2010 | US7651996 1 wt.% insulin, 2 wt. % oxacyclohexadecane-2-one as permeation enhancer, 1% wt. cottenseed oil, 0.6 wt.% Sorbitan, 0.7 wt. % Polysorbate 20, 94.3 wt. % water, buffer amounts of 0.3 wt. % citric acid (monohydrate) and 0.1 wt. % sodium citrate (dihydrate); nasal drug delivery |
| 01/26/2010 | US7651678 Methods to impair hematologic cancer progenitor cells and compounds related thereto |
| 01/26/2010 | CA2222524C Somatostatin peptides |
| 01/21/2010 | WO2010009220A2 Radiolabelled trp m8 receptor ligands |
| 01/21/2010 | WO2010009186A1 Liposome formulation having hydrophilic and hydrophobic pharmaceutical compounds co-encapsulated therein |
| 01/21/2010 | WO2010007329A2 Novel method for measuring insulin resistance |
| 01/21/2010 | WO2010006755A2 A compound for imaging cell death |
| 01/21/2010 | WO2010006616A2 Method and kit for examination of cells using n-(9-acridinyl)maleimide (nam) or using 7-diethylamino-3-((4'-(iodoacetyl)amino)phenyl)-4-methylcoumarin (cpi) |